Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5205683 | 0.98 | HRH3 (1.00) | HRH3KCNH2CYP2D6 | |
| SCHEMBL4229898 | 0.97 | HRH3 (0.94) | HRH3KCNH2CYP2D6 | |
| SCHEMBL2540367 | 0.84 | HRH3 (0.71) | HRH3KCNH2 | |
| SCHEMBL247758 | 0.84 | HRH3 (0.71) | HRH3 | |
| SCHEMBL7061476 | 0.82 | HRH3 (0.71) | HRH3 | |
| SCHEMBL506979 | 0.82 | HRH3 (0.71) | HRH3 | |
| SCHEMBL3308476 | 0.81 | HRH3 (0.67) | HRH3KCNH2CYP2D6 | |
| SCHEMBL4464014 | 0.81 | HRH3 (0.68) | HRH3KCNH2 | |
| SCHEMBL21130985 | 0.80 | HRH3 (0.67) | HRH3 | |
| SCHEMBL5024491 | 0.80 | HRH3 (0.71) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1311482-B1 | NON-IMIDAZOLE ARYLOXYPIPERIDINES AS H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARM INC (US) | 2007-02-21 | — | — | EP | claimed |
| US-20050227979-A1 | Non-imidazole aryloxypiperidines | APODACA RICHARD | 2005-10-13 | — | — | US | claimed |
| EP-1311482-A2 | NON-IMIDAZOLE ARYLOXYPIPERIDINES AS H3 RECEPTOR LIGANDS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-05-21 | — | — | EP | claimed |
| US-20020040024-A1 | Non-imidazole aryloxypiperidines | NORTEL NETWORKS LIMITED (CA) | 2002-04-04 | — | — | US | claimed |
| WO-2002012190-A2 | NON-IMIDAZOLE ARYLOXYPIPERIDINES AS H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-14 | — | — | WO | claimed |
| US-7241778-B2 | Non-imidazole aryloxypiperidines | ORTHO MCNEIL PHARMACEUTICAL, INC (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241778-B2 | Non-imidazole aryloxypiperidines | ORTHO MCNEIL PHARMACEUTICAL, INC (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241778-B2 | Non-imidazole aryloxypiperidines | ORTHO MCNEIL PHARMACEUTICAL, INC (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1311482-B1 | NON-IMIDAZOLE ARYLOXYPIPERIDINES AS H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARM INC (US) | 2007-02-21 | — | — | EP | disclosed |
| US-7071191-B2 | Non-imidazole aryloxypiperidines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-07-04 | — | — | US | disclosed |
| US-20060052597-A1 | Aryloxyalkylamine derivatives as h3 receptor ligands | BEST DESMOND J | 2006-03-09 | — | — | US | disclosed |
| US-20050227979-A1 | Non-imidazole aryloxypiperidines | APODACA RICHARD | 2005-10-13 | — | — | US | disclosed |
| EP-1554260-A1 | ARYLOXYALKYLAMINE DERIVATIVES AS H3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004037800-A1 | ARYLOXYALKYLAMINE DERIVATES AS H3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
| EP-1311482-A2 | NON-IMIDAZOLE ARYLOXYPIPERIDINES AS H3 RECEPTOR LIGANDS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-05-21 | — | — | EP | disclosed |
| US-20020040024-A1 | Non-imidazole aryloxypiperidines | NORTEL NETWORKS LIMITED (CA) | 2002-04-04 | — | — | US | disclosed |
| WO-2002012190-A2 | NON-IMIDAZOLE ARYLOXYPIPERIDINES AS H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052597-A1 | Aryloxyalkylamine derivatives as h3 receptor ligands | HRH3, HTR6, HTR4 | HRH3 1/4885KCNH2 665/4885CYP2D6 1355/4885 |
| US-20020040024-A1 | Non-imidazole aryloxypiperidines | HRH2, HRH4, HRH3 | HRH3 3/4885KCNH2 703/4885CYP2D6 730/4885 |
| US-20050227979-A1 | Non-imidazole aryloxypiperidines | HRH2, HRH4, HRH3 | HRH3 3/4885KCNH2 703/4885CYP2D6 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.